New Investigational Stimulation Protocol for Treatment of Major Depression Disorder (MDD) - Trial NCT06357832
Access comprehensive clinical trial information for NCT06357832 through Pure Global AI's free database. This phase not specified trial is sponsored by Brainsway and is currently Not yet recruiting. The study focuses on Major Depressive Disorder. Target enrollment is 104 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Brainsway
Timeline & Enrollment
N/A
Apr 15, 2024
Dec 15, 2024
Primary Outcome
Change in Hamilton Depression Rating Scale (HDRS)-21 score in the investigational group
Summary
The BrainsWay Deep Transcranial Magnetic Stimulation (Depp TMS) device is intended for the
 treatment of depressive episodes in patients suffering from Major Depressive Disorder (MDD).
 The device technology is based on the application of deep brain TMS by means of repetitive
 pulse trains at a determined frequency. The purpose of the current study is to evaluate the
 safety and effectiveness of a new investigational stimulation protocol delivered with the
 BrainsWay Deep TMS device, for the treatment of MDD, demonstrating that it is non-inferior to
 the current standard-of-care stimulation protocol, in a randomized, controlled study.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06357832
Device Trial